Use of Hematopoietic Growth Factor in the Management of Hematological Side Effects Associated to Antiviral Treatment for Hcv Hepatitis
2010

Managing Blood Issues in Hepatitis C Treatment

publication 10 minutes Evidence: moderate

Author Information

Author(s): Mancino Paola, Falasca Katia, Ucciferri Claudio, Pizzigallo Eligio, Vecchiet Jacopo

Primary Institution: Università Cattolica del Sacro Cuore

Hypothesis

Can hematopoietic growth factors improve the management of hematological side effects during antiviral treatment for hepatitis C?

Conclusion

Hematopoietic growth factors may help manage blood-related side effects of hepatitis C treatment, but their impact on sustained viral response is still uncertain.

Supporting Evidence

  • Hematological abnormalities are common during hepatitis C treatment.
  • Growth factors are used off-label to manage anemia and neutropenia.
  • Maintaining ribavirin dosage is crucial for treatment success.

Takeaway

Doctors are using special medicines to help patients with hepatitis C who have low blood counts from their treatment, but it's not clear if this helps them get better.

Methodology

The review involved a literature search of peer-reviewed articles from 1991 to 2010 regarding hematological side effects and management in hepatitis C treatment.

Potential Biases

Potential bias due to the reliance on off-label use of growth factors and variability in treatment regimens.

Limitations

The review highlights the lack of official guidelines and the need for more studies to confirm the benefits of growth factors.

Participant Demographics

The review discusses various demographics affected by hepatitis C, including age and gender factors influencing anemia.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.4084/MJHID.2010.003

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication